Bioxcel Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
BioXcel Therapeutics, Inc. will hold its 2025 Annual Meeting to vote on director elections, auditor ratification, executive compensation, and a proposed reverse stock split to maintain Nasdaq compliance.
NASDAQ
DEF 14A: BioXcel Therapeutics Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing
BioXcel Therapeutics is asking stockholders to approve a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.
NASDAQ
DEFA14A: BioXcel Therapeutics Sets Date for 2024 Annual Meeting, Seeks Stockholder Approval on Key Proposals
BioXcel Therapeutics has scheduled its 2024 Annual Meeting for June 10, 2024, and is seeking stockholder votes on several proposals, including the election of directors, ratification of the company's accounting firm, executive compensation, and amendments to the company's certificate of incorporation.
NASDAQ
BioXcel Therapeutics is holding its annual stockholder meeting on June 10, 2024, to vote on key proposals including increasing authorized shares and officer exculpation.